265 related articles for article (PubMed ID: 15045868)
1. [The formation and significance of antibodies to interferon beta during immunomodulating treatment of multiple sclerosis].
Bartosik-Psujek H; Stelmasiak Z
Neurol Neurochir Pol; 2004; 38(1 Suppl 1):S53-6. PubMed ID: 15045868
[TBL] [Abstract][Full Text] [Related]
2. Neutralizing antibodies (NABS) and interferon beta-1b therapy of multiple sclerosis.
Horowski R; Stürzebecher CS; Kapp JF
Funct Neurol; 2001; 16(2):117-28. PubMed ID: 11495417
[No Abstract] [Full Text] [Related]
3. Immunogenicity of interferon beta: differences among products.
Bertolotto A; Deisenhammer F; Gallo P; Sölberg Sørensen P
J Neurol; 2004 Jun; 251 Suppl 2():II15-II24. PubMed ID: 15264108
[TBL] [Abstract][Full Text] [Related]
4. Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis.
Vartanian T; Sölberg Sørensen P; Rice G
J Neurol; 2004 Jun; 251 Suppl 2():II25-30. PubMed ID: 15264109
[TBL] [Abstract][Full Text] [Related]
5. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b.
Antonelli G; Simeoni E; Bagnato F; Pozzilli C; Turriziani O; Tesoro R; Di Marco P; Gasperini C; Fieschi C; Dianzani F
J Neurol Sci; 1999 Oct; 168(2):131-6. PubMed ID: 10526196
[TBL] [Abstract][Full Text] [Related]
6. Optimising MS disease-modifying therapies: antibodies in perspective.
Giovannoni G
J Neurol; 2004 Sep; 251 Suppl 5():v30-v35. PubMed ID: 15549353
[TBL] [Abstract][Full Text] [Related]
7. Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients.
Jensen PE; Sellebjerg F; Søndergaard HB; Sørensen PS
Eur J Neurol; 2012 Oct; 19(10):1311-7. PubMed ID: 22564111
[TBL] [Abstract][Full Text] [Related]
8. A novel assay to detect low-titred antibodies to interferon beta in multiple sclerosis patients.
Di Marco P; Pagnotti P; Bellomi F; De Vito G; Sessa E; Bagnato F; Scagnolari C; Bramanti P; Antonelli G
New Microbiol; 2006 Jan; 29(1):11-8. PubMed ID: 16608120
[TBL] [Abstract][Full Text] [Related]
9. The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies.
Pachner AR; Dail D; Pak E; Narayan K
J Neuroimmunol; 2005 Sep; 166(1-2):180-8. PubMed ID: 16005084
[TBL] [Abstract][Full Text] [Related]
10. [Long-term effect of neutralizing antibodies to interferon beta-1 b in patients with multiple sclerosis].
Río J; Tintoré M; Téllez N; Nos C; Galán I; Montalbán X
Med Clin (Barc); 2005 Feb; 124(4):140-1. PubMed ID: 15713243
[TBL] [Abstract][Full Text] [Related]
11. [Neutralizing antibodies in patients with multiple sclerosis treated with interferon beta-1b].
Río J; Barberà N; Tintoré M; Brieva L; Montalbán X
Med Clin (Barc); 2000 Feb; 114(5):169-70. PubMed ID: 10738721
[TBL] [Abstract][Full Text] [Related]
12. [Beta-interferon neutralizing antibodies. Do they have clinical value in patients with multiple sclerosis?].
Romero López J; Maciñeiras Montero JL
Med Clin (Barc); 2005 Feb; 124(4):144-5. PubMed ID: 15713245
[No Abstract] [Full Text] [Related]
13. Assessment and management of neutralizing antibodies in patients with multiple sclerosis.
Hartung HP; Munschauer FE
J Neurol; 2004 Jun; 251 Suppl 2():II40-2. PubMed ID: 15264111
[TBL] [Abstract][Full Text] [Related]
14. Neutralizing antibodies to interferon.
Noronha A
Neurology; 2007 Jun; 68(24 Suppl 4):S16-22. PubMed ID: 17562846
[TBL] [Abstract][Full Text] [Related]
15. Antibodies to interferon beta in patients with multiple sclerosis receiving CinnoVex, rebif, and betaferon.
Zare N; Zarkesh-Esfahani SH; Gharagozloo M; Shaygannejad V
J Korean Med Sci; 2013 Dec; 28(12):1801-6. PubMed ID: 24339712
[TBL] [Abstract][Full Text] [Related]
16. On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis.
van Beers MM; Jiskoot W; Schellekens H
J Interferon Cytokine Res; 2010 Oct; 30(10):767-75. PubMed ID: 20874254
[TBL] [Abstract][Full Text] [Related]
17. Treatment of multiple sclerosis with interferon beta 1b.
Dhib-Jalbut S; McFarland HF
Baillieres Clin Neurol; 1997 Oct; 6(3):467-80. PubMed ID: 10101584
[TBL] [Abstract][Full Text] [Related]
18. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.
Pachner AR; Cadavid D; Wolansky L; Skurnick J
Neurology; 2009 Nov; 73(18):1485-92. PubMed ID: 19884576
[TBL] [Abstract][Full Text] [Related]
19. Fate of multiple sclerosis patients positive for neutralising antibodies towards interferon beta shifted to alternative treatments.
Malucchi S; Capobianco M; Gilli F; Marnetto F; Caldano M; Sala A; Bertolotto A
Neurol Sci; 2005 Dec; 26 Suppl 4():S213-4. PubMed ID: 16388361
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of an interferon-beta1a product.
Kauffman MA; Sterin-Prync A; Papouchado M; González E; Vidal AJ; Grossberg SE; Chuppa S; Odoriz B; Vrech C; Diez RA; Ferro HH
Int J Immunopathol Pharmacol; 2011; 24(2):499-504. PubMed ID: 21658324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
